Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

181. Criterion validation of screening tools for early detection of oral, breast and cervical cancers: systematic review and meta-analysis

Criterion validation of screening tools for early detection of oral, breast and cervical cancers: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

182. Cost-effectiveness analysis of analog mammography compared to digital mammography in screening of women with breast cancer: a systematic review

Cost-effectiveness analysis of analog mammography compared to digital mammography in screening of women with breast cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

183. Comparative efficacy, safety and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis

Comparative efficacy, safety and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

184. Association between breast density and breast cancer risk in Asian women

Association between breast density and breast cancer risk in Asian women Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

185. Clinical efficacy of weekly cisplatin chemotherapy (WCCT) for treatment of patients with breast cancer (BC): a systematic review protocol

Clinical efficacy of weekly cisplatin chemotherapy (WCCT) for treatment of patients with breast cancer (BC): a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

186. Comparative clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a network meta-analysis of randomized controlled trials

Comparative clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a network meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

187. 18F-FDG PET/CT in the staging of inflammatory breast cancer: a systematic review

18F-FDG PET/CT in the staging of inflammatory breast cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

188. A systematic review of pertuzumab, trastuzumab and docetaxel for patients with HER2-positive breast cancer

A systematic review of pertuzumab, trastuzumab and docetaxel for patients with HER2-positive breast cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

189. A systematic review and meta-analysis of eHealth technology interventions for endocrine therapy patients with breast cancer

A systematic review and meta-analysis of eHealth technology interventions for endocrine therapy patients with breast cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

190. Adult weight gain and the risk of postmenopausal breast cancer in Asian women: a dose-response meta-analysis

Adult weight gain and the risk of postmenopausal breast cancer in Asian women: a dose-response meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

191. A systematic review of weekly cisplatin for treating patients with breast cancer

A systematic review of weekly cisplatin for treating patients with breast cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

192. Optimal duration of adjuvant trastuzumab in treatment of early human epidermal growth factor receptor-2 (HER2) positive breast cancer: protocol for a network meta-analysis of randomized trials

Optimal duration of adjuvant trastuzumab in treatment of early human epidermal growth factor receptor-2 (HER2) positive breast cancer: protocol for a network meta-analysis of randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

193. Physical activity and exercise related effects in patients with metastatic breast cancer: a systematic review

Physical activity and exercise related effects in patients with metastatic breast cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

194. Interventions for radiation-induced fibrosis in patients with head and neck and breast cancer: systematic review

Interventions for radiation-induced fibrosis in patients with head and neck and breast cancer: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

195. PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis

PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

196. Overall survival results of early detection and treatment of brain metastasis in HER2 positive breast cancer: a systematic review and meta-analysis

Overall survival results of early detection and treatment of brain metastasis in HER2 positive breast cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

197. Effects of yoga on life quality improvement for breast cancer patients: a meta-analysis of randomized controlled trials

Effects of yoga on life quality improvement for breast cancer patients: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

198. Long non-coding RNA serve as a potential predictor biomarker for breast cancer: a systematic review and meta-analysis

Long non-coding RNA serve as a potential predictor biomarker for breast cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

199. Lifestyle interventions through participatory action research: a systematic review of alcohol and other breast cancer behavioural risk factors of diet, physical activity and smoking

Lifestyle interventions through participatory action research: a systematic review of alcohol and other breast cancer behavioural risk factors of diet, physical activity and smoking Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

200. The relationship between tumour budding and prognosis in patients with invasive ductal breast cancer - a systematic review and meta-analysis

The relationship between tumour budding and prognosis in patients with invasive ductal breast cancer - a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO